{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:04:11Z","timestamp":1790201051388,"version":"4.1.0"},"reference-count":57,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>While hyperammonemia is traditionally associated with decompensated cirrhosis, emerging evidence suggests that disturbances in nitrogen homeostasis contribute to disease progression in earlier stages of steatohepatitis and fibrosis. L\u2010ornithine L\u2010aspartate (LOLA), an established ammonia scavenger, targets key pathophysiological mechanisms shared by metabolic dysfunction\u2010associated steatotic liver disease (MASLD), including oxidative stress, mitochondrial dysfunction and hepatic stellate cell activation. This systematic review synthesizes current experimental and clinical research to evaluate the potential therapeutic role of LOLA in MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase and SCOPUS was conducted up to December 1, 2025, following PRISMA 2020 guidelines. Eligible studies included experimental (in vivo\/in vitro) and clinical trials evaluating the effects of LOLA or L\u2010aspartate on hepatic steatosis, inflammation, or fibrosis in the context of MASLD. Data extraction and quality assessment were performed independently by two reviewers using appropriate tools for animal and human studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen studies were included, comprising 10 experimental pre\u2010clinical models (9 in\u00a0vivo animal studies and 1 in\u00a0vitro study) and 9 clinical studies involving approximately 1671 participants. Experimental studies consistently demonstrated that LOLA intervention ameliorates hepatic steatosis, inflammation and collagen deposition. Identified molecular mechanisms included the activation of the LKB1\u2010AMPK axis, restoration of mitochondrial bioenergetics and modulation of the gut\u2010liver\u2010muscle axis. In clinical studies, results from three randomized controlled trials (RCTs) indicated significant improvements in liver enzymes (ALT, AST) and lipid profiles, with reductions in hepatic steatosis. Evidence from six observational and open\u2010label studies corroborated these biochemical improvements and further demonstrated significant reductions in blood ammonia levels, improved intrahepatic microcirculation and reduced liver stiffness and patient\u2010reported fatigue. However, clinical evidence remains limited by study heterogeneity and a lack of large\u2010scale randomized trials using specific MASLD criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preclinical evidence suggests that LOLA exerts pleiotropic hepatoprotective effects in MASLD by targeting hyperammonemia\u2010induced fibrosis and metabolic dysregulation. While growing clinical data indicate benefits in biochemical normalization, structural improvement and symptom relief, further robust clinical research is required to validate these findings and establish LOLA as a standard therapeutic option for MASLD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/eci.70185","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:05:57Z","timestamp":1770462357000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Can ammonia scavenging treat MASLD? Evaluating the evidence for L\u2010ornithine L\u2010aspartate\u2014A systematic review"],"prefix":"10.1111","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-271X","authenticated-orcid":false,"given":"Abdulrahman","family":"Ismaiel","sequence":"first","affiliation":[{"name":"2nd Department of Internal Medicine \u2018Iuliu Hatieganu\u2019 University of Medicine and Pharmacy  Cluj\u2010Napoca Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Ciornolutchii","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine \u2018Iuliu Hatieganu\u2019 University of Medicine and Pharmacy  Cluj\u2010Napoca Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan\u2010Lucian","family":"Popa","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine \u2018Iuliu Hatieganu\u2019 University of Medicine and Pharmacy  Cluj\u2010Napoca Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan L.","family":"Dumitrascu","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine \u2018Iuliu Hatieganu\u2019 University of Medicine and Pharmacy  Cluj\u2010Napoca Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101898"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100485"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062394"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1058101"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2007.06.026"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado1648"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.040"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001174"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136518"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1024-1"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1023-2"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1020-5"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14617"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v16.i6.871"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)31398-2"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.102050"},{"issue":"4","key":"e_1_2_10_26_1","first-page":"A67","article-title":"P79 clearing the mind: LOLA's promise in hepatic encephalopathy\u2010 a real world experience","volume":"74","author":"McAuley C","year":"2025","journal-title":"Gut"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114921"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.808497"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16053"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1051157"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.33647\/2074-5982-16-3-77-80"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1927633"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107294"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121773"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v16.i5.832"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136839"},{"key":"e_1_2_10_37_1","first-page":"146","article-title":"Hepatoprotective effects of L\u2010ornithine\u2010L\u2010aspartate in toxic liver injury","volume":"3","author":"Oleshchuk O","year":"2021","journal-title":"Pharmacol Online"},{"key":"e_1_2_10_38_1","first-page":"219","article-title":"Efficacy of L\u2010ornithin\u2010L\u2010aspartate\u2010granules in chronic liver diseases","volume":"52","author":"Gr\u00fcngreiff K","year":"2001","journal-title":"Med Welt"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.20514\/2226-6704-2016-6-5-45-52"},{"key":"e_1_2_10_40_1","first-page":"6","article-title":"Use of oral L\u2010ornithine\u2010L\u2010aspartate (LOLA) in hyperammonemia in patients with precirrhotic chronic liver disease","volume":"16","author":"Ageeva EA","year":"2017","journal-title":"Eff Pharmaco"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.31146\/1682-8658-ecg-176-4-24-30"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.22416\/1382-4376-2021-31-4-31-36"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","unstructured":"KizovaEA PotekhinaYP.Effect of l\u2010ornithine\u2010l\u2010aspartate therapy on the hyperammonemia level and results of the number connection test of patients suffering from nonalcoholic fatty liver disease.2020.","DOI":"10.31146\/1682-8658-ecg-169-9-80-84"},{"issue":"7","key":"e_1_2_10_44_1","first-page":"528","article-title":"Aspartate\u2010ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple\u2010dose parallel controlled clinical trial","volume":"21","author":"Tian LY","year":"2013","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"7","key":"e_1_2_10_45_1","first-page":"17","article-title":"Use of L\u2010ornithine\u2010L\u2010aspartate in patients with non\u2010alcoholic fatty liver disease","volume":"1","author":"Sas EI","year":"2018","journal-title":"Med Alphabet"},{"key":"e_1_2_10_46_1","first-page":"25","article-title":"L\u2010ornithine\u2010L\u2010aspartate in the treatment of non\u2010alcoholic fatty liver disease in obese patients with signs of metabolic syndrome","volume":"4","author":"Zhuravleva L","year":"2015","journal-title":"Practitioner"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040506"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.16381"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115640"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00970-9"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.05.005"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094256"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000491429"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041778"},{"issue":"5","key":"e_1_2_10_55_1","article-title":"L\u2010ornithine L\u2010aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"5","author":"Goh ET","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.019"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2006.108506"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-08844-z"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.70185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/eci.70185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.70185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:46:06Z","timestamp":1778935566000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.70185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/eci.70185"],"URL":"https:\/\/doi.org\/10.1111\/eci.70185","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70185"}}